Sales of generic for Galvus are not affected

despite the results of Galvus patent litigation

Material patents have already expired in March

A reversal occurred once again in the patent dispute for the DPP-4 inhibitor-based diabetes treatment Galvus.

 

The original signing Novartis won the remand hearing that took place after the Supreme Court's dismissal.

 

The pharmaceutical industry believes that the decision will not have a significant impact on sales of generic for Galvus, which was released earlier this year.

 

This is because the material patent in question expired during the dispute.

 

According to the pharmaceutical industry on the 4th, the Korean Intellectual Property Tribunal overturned the previous ruling in a lawsuit to invalidate the extension of the duration of the material patent of Vildagliptin and decided to win Novartis.

 

The Galvus patent dispute has been complicated by the reversal.

 

Ahngook and Hanmi filed a trial in 2017, claiming that some of the extended duration of material patent of Galvus was invalid.

 

In the first trial, Generic companies won.

 

In 2019, the Patent Tribunal ruled that 187 days of the extended duration were invalid.

 

Novartis won the second trial.

 

In 2020, the Patent Court ruled that 55 of 187 days were invalid.

 

The case went to the Supreme Court on Novartis' appeal.

 

In October last year, the Supreme Court ruled against the company and sided with the company.

 

It was a ruling that Novartis, which won the second trial, was not eligible to appeal.

 

The case was dealt with in the first trial.

 

In the end, the Patent Tribunal took Novartis' side.

 

Even 55 days recognized by the patent court did not constitute invalidity.

 

However, the pharmaceutical industry predicts that there will be no problem with the sale and prescription of generic for Galvus even with the Korean Intellectual Property Tribunal's decision.

 

This is because the material patent expired during the dispute.

 

The Galvus material patent expired on March 4.

 

Hanmi Pharmaceutical, Ahngook Pharmaceutical, Angooknewpharm, Kyongbo, Korea United Pharmaceutical, Samjin, and Shin Poong then released the generic.

 

Hanmi Pharmaceutical, which launched Vildagle as generic for Galvus in January this year, is also determined to continue marketing and sales of its products as usual.

 

An official from Hanmi said, "The material patent of Vildagliptin has already expired on March 4, and there is no impact on the distribution, sale, and prescription of the previously released Vildagle.

 

We plan to appeal to continue to focus the company's capabilities for the success of Vildagle."